Avid Bioservices Inc (CDMO)

[keep_trying]

Geo, I see PPHM's value and timing to that prospective buyout or big licensing deal as being directly proportional to how well PPHM demonstrates it is holding its financials together while it proceeds Bavi and Cotara technology development through trials. PPHM can get to that higher valuation by muddling along with just enough resources to keep trials going until PPHM initiates their first Bavi Phase 3 trials. They can also get to that higher value by bringing in "surplus" funding that demonstrates that they have the wherewithall to do the trial work without running out of resources. In that sense, if PPHM brings in funding through interim partnering deals or perhaps more DTRA funding, that can speed along the process. Regardless, PPHM has shown it has procured enough funding to keep trials moving along at least another year, sufficient time to bring closure to some of the ongoing Phase 2 trials and set up the launch of Phase 3 trials.

Who has time on their side for making a deal for Bavi if the ongoing trials continue to show Bavi is outperforming standard of care, interested pharma or PPHM? If there is competition between pharmas in play, it would seem PPHM is at least carrying more cards. What did the Affitech deal for 2C3 really bring in benefits to PPHM?

Best wishes and IMO.
KT